You feel different, and the report says "normal." That gap is real, and often it comes down to one moving number on a single day: FSH.
If your cycle used to be predictable and your moods steady, and now sleep is broken and the rules seem to have changed, you are not imagining it, and you are not "too young" to ask questions. The frustrating part is that the lab most people expect to explain perimenopause, follicle-stimulating hormone (FSH), is one of the least reliable single tests during this exact stage of life. Understanding why can change how you approach the whole conversation.
What FSH actually measures
FSH is a hormone made by the pituitary gland. Its job is to stimulate the ovaries to mature follicles each cycle. As the ovarian reserve declines with age, the ovaries respond less predictably, so the pituitary tends to send more FSH to get the same job done. Over time, higher FSH is one of the signals that the menopausal transition is underway [1][2].
That sounds tidy. In practice, perimenopause is the opposite of tidy.
Why one draw can mislead
During the menopausal transition, ovarian function does not decline in a smooth line. It swings. Estradiol can spike higher than in your twenties one month and drop the next, and FSH rises and falls along with it. Research from the Study of Women's Health Across the Nation (SWAN) and others has documented that hormone levels in perimenopause are highly variable from cycle to cycle and even within a single cycle [3][4].
This is the core problem with a single FSH draw at 43:
- Timing matters. FSH is normally measured in the early follicular phase (roughly days 2 to 5 of a cycle). Drawn at a different point, the same person can produce a very different value [1].
- One number is a snapshot, not a trend. Because levels fluctuate, a single "normal" FSH does not rule out perimenopause, and a single high FSH does not confirm menopause on its own [2][4].
- Symptoms can precede lab changes. Sleep disruption, mood shifts, and cycle changes can show up while FSH is still bouncing within a "normal-looking" range on the day you happened to get drawn.
This is why major guidance stresses that in women over 45 with typical symptoms and changing cycles, perimenopause is generally a clinical diagnosis based on symptoms and menstrual pattern, not on a single hormone level [1][5]. FSH testing has more of a role at younger ages or in specific situations, and even then it is usually interpreted across repeated measurements and alongside other data.
cycle day · marker = Common draw day
Source: [1] Menopause: diagnosis and management (NICE Guideline NG23), [2] Follicle-Stimulating Hormone (FSH) Levels Test, MedlinePlus
What providers often order alongside FSH
Because FSH alone is a weak solo witness, an independent provider mapping a midlife picture will typically look at a broader panel to see the full context. What gets ordered is individualized, but commonly considered categories include:
- Thyroid function (TSH, sometimes free T4). Thyroid disorders are common in midlife women and can mimic perimenopausal symptoms like fatigue, weight change, and mood shifts, so ruling them in or out matters [6].
- Estradiol. Read together with FSH and clinical picture, not in isolation, because it also fluctuates [3].
- Metabolic markers such as fasting glucose, HbA1c, and a lipid panel, because cardiometabolic risk shifts across the menopausal transition [7].
- Iron studies and a complete blood count, since heavy or irregular bleeding is common in perimenopause and can affect iron [1].
The point of a fuller baseline is not to collect labs for their own sake. It is to give a provider enough context that a single fluctuating number does not get treated as the whole story.
Source: [3] Randolph JF et al., Change in Estradiol and Follicle-Stimulating Hormone Across the Menopausal Transition (SWAN), J Clin Endocrinol Metab, [4] Harlow SD et al., Executive Summary of the Stages of Reproductive Aging Workshop +10 (STRAW+10), J Clin Endocrinol Metab, [6] Hypothyroidism (Underactive Thyroid), NIDDK, National Institutes of Health
Reading the report like a provider would
A thoughtful reading holds several things at once:
1. Your symptom pattern and its timeline. Sleep, mood, cycle regularity, and how recently things shifted.
2. Your cycle day when blood was drawn, which frames how to interpret FSH and estradiol.
3. The trend, where available, rather than a lone value.
4. Alternative explanations, like thyroid or iron, that a broader panel can surface.
Held this way, "normal" on one FSH stops being a verdict and becomes one data point in a larger map. That reframing is often the difference between being sent home and being taken seriously.
What this does not mean
A fluctuating FSH does not mean testing is pointless. It means the interpretation has to respect the biology. It also does not mean any particular treatment is indicated. Whether hormone therapy or any other approach is appropriate is a clinical decision made by a licensed provider based on your full history, preferences, and risk profile, not something a lab value decides on its own [5].
This article is educational and is not medical advice. It cannot diagnose you or tell you what to take. Its aim is to help you walk into a conversation with better questions and a clearer sense of what the data can and cannot say.
Where Velri fits
Velri is a technology and coordination company, not a medical provider. Velri does not practice medicine, diagnose, or prescribe. What Velri can do is coordinate the pieces that are hard to line up on your own: ordering a comprehensive baseline lab panel, organizing those results so they are readable, and connecting you with an independent, physician-led Provider Group for a visit where a licensed provider reviews your history, symptoms, and labs together.
If, and only if, an independent provider determines it is clinically appropriate, any prescribed medication would be dispensed by an independent, licensed pharmacy. A prescription is never guaranteed; that decision rests entirely with the independent provider. Some longevity and hormone-related plans may involve compounded medications. Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri's coverage starts in Nevada, with more states rolling out over time. The goal is to let you begin with the data you actually wanted first: a real baseline, read in context, with an independent provider who takes midlife change seriously rather than waving off a single "normal" number.
